Table 2.
Baseline poliovirus serum neutralising antibody seroprevalence and median antibody titres in those aged 24–59 months
| Needle and syringe (n=582) | Disposable syringe jet injector (n=574) | Intradermal adapter (n=527) | Total (n=1683) | |
|---|---|---|---|---|
| Poliovirus type 1 | ||||
| Seroprevalence | 550 (94·5%; 92·3–96·0) | 542 (94·4%; 92·1–96·0) | 488 (92·6%; 90·0–94·5) | 1580 (93·9%; 92·5–94·9) |
| Median antibody titres | 362 (274–362) | 362 (362–446) | 274 (223–362) | 362 (274–362) |
| Poliovirus type 2 | ||||
| Seroprevalence | 567 (97·4%; 95·8–98·4) | 553 (96·3%; 94·5–97·5) | 510 (96·8%; 94·9–98·0) | 1630 (96·9%; 95·9–97·5) |
| Median antibody titres | 274 (223–274) | 362 (274–362) | 222 (223–274) | 274 (274–274) |
| Poliovirus type 3 | ||||
| Seroprevalence | 520 (89·3%; 86·5–91·5) | 485 (84·5%; 81·3–87·1) | 435 (82·5%; 79·0–85·5) | 1440 (85·6%; 83·8–87·1) |
| Median antibody titres | 91 (91–111) | 91 (69–111) | 69 (56–91) | 91 (69–91) |
Data presented as n (%, 95% CI), or median (95% CI). Seroprevalence is defined as the number of participants with a serum neutralising antibody titre of ≥8 as a proportion of all participants tested.